LivaNova PLC (NASDAQ:LIVN) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – ...

Adjusted Gross Profit % Adjusted SG&A % Adjusted R&D % Adjusted R&D % $318.6• Net revenue increased 9.6 percent on a constant-currency basis • Foreign currency had an unfavorable impact on net revenue of ~$3M, or approximately 1 percent Adjusted Operating Margin % Note: Net revenue, total revenue excluding revenue from the ACS segment wind down, adjusted diluted EPS and adjusted gross profit, adjusted SG&A, adjusted R&D, and adjusted operating margin all as a percentage of net revenue are non-GAAP measures. ...

LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 17.72%. A quarter ago, it was expected that this medical technology company would post earnings of $0.45 per share when it actually produced earnings of $0.73, delivering a surprise of 62.22%. Over the last four quarters, ...

EXHIBIT 99.1 London, July 31, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. • Announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study on June 6, 2024. Following additional in-depth analyses of the data, intends to pursue U.S. Centers for Medicare and Medicaid Services coverage for VNS Therapy™ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its cha ...

Financial Data and Key Metrics Changes - Revenue for the first quarter was $295 million, an increase of 12% compared to 2023, and a 14% increase when excluding the impact of the ATS segment wind down [52][36] - Adjusted operating income was $53 million, compared to $27 million in the first quarter of last year, with an adjusted operating income margin of 18% compared to 10% in the first quarter of 2023 [14][35] - Adjusted diluted earnings per share was $0.73, up from $0.43 in the first quarter of 2023 [54] - Total debt increased to $624 million from $587 million at year-end 2023, driven by a private offering of convertible senior notes [16] Business Line Data and Key Metrics Changes - Cardiopulmonary segment revenue was $156 million, a 16% increase year-over-year, with heart-lung machine revenue increasing more than 20% driven by the Essenz product [10] - Difficult-to-treat depression revenue was $2 million for the quarter, with an anticipated total of approximately $7 million for the full year [11] - Epilepsy revenue increased by 11% compared to the first quarter of 2023, with U.S. epilepsy revenue growing 13% year-over-year [28] Market Data and Key Metrics Changes - U.S. new patient implants in epilepsy grew by 4% year-over-year, while replacement implants grew by 5% [28] - International revenue is expected to grow in high single-digits, with U.S. new patients projected to continue mid-single-digit growth [29] Company Strategy and Development Direction - The company is focused on three key areas: execution, innovation, and talent, aiming for sustainable above-market growth while improving profitability and cash flow [7][26] - The strategy includes refining the business portfolio, such as winding down the Advanced Circulatory Support segment, to focus resources on growth areas [25] - The company plans to continue investing in critical capabilities to support innovation and growth, particularly in the cardiopulmonary and epilepsy segments [40][59] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to maintain double-digit revenue growth, emphasizing the importance of innovation and execution [8][41] - The outlook for the remainder of the year includes a focus on building on the strength of core businesses and strategically targeting compelling opportunities based on clinical study results [59][40] Other Important Information - Adjusted R&D expense was $43 million, down from $46 million in the first quarter of 2023, with R&D as a percentage of net revenue decreasing to 15% [53] - The company anticipates a full-year adjusted effective tax rate of approximately 21% [37] Q&A Session Summary Question: Sustainability of strong epilepsy growth - Management indicated that sustainability comes from continuous upgrades to the Essenz heart-lung machine and strong commercial execution in neuromodulation [43][44] Question: Role of Chief Innovation Officer - The Chief Innovation Officer is tasked with improving innovation processes and assessing areas for future development, particularly in obstructive sleep apnea and difficult-to-treat depression [45][47] Question: Oxygenator business capacity expansion - Management confirmed that capacity expansion is on track and they are monitoring competitive dynamics in the market [50][51] Question: Timing for sleep program commercial preparation - Commercial preparation for the sleep program will be cautious until key clinical data is available, with minimal spending anticipated in 2024 [76] Question: Heart-lung machine growth expectations - Management expects continued growth in the heart-lung machine segment, capitalizing on the replacement cycle and strong technology [71] Question: Impact of RECOVER trial results on strategy - The outcome of the RECOVER trial will significantly influence future strategic decisions, with a focus on clinical benefits and competitive positioning [135][136]

| --- | --- | --- | --- | --- | |------------------------------|-------|-------|-------|-------| | | | | | | | Liva Nova First Quarter 2024 | | | | | | Earnings Update | | | | | | May 1, 2024 | | | | | Safe Harbor 2 forward-looking statements, which are made only as of the date of this material. 3 • Trademarks for LivaNova's Neuromodulation systems, the VNS Therapy™ System, the VITARIA™ System and LivaNova's proprietary pulse generator products: Model 102 (Pulse™), Model 102R (Pulse Duo™), Model 103 (Demipu ...

LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 62.22%. A quarter ago, it was expected that this medical technology company would post earnings of $0.79 per share when it actually produced earnings of $0.87, delivering a surprise of 10.13%.Over the last four quarters, ...

EXHIBIT 99.1 NEWS RELEASE LivaNova Reports First-Quarter 2024 Results London, May 1, 2024 – LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance. Financial Summary and Highlights (1) "In the first quarter, LivaNova achieved double-digit revenue and operating income growth in both the Cardiopulmonary and Neuromodulation segments," said Vladimir Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37599 LivaNova PLC (Exact name of registrant as specified in its charter) England and Wales ................... 98-126815 ...